IN2012DN03312A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03312A IN2012DN03312A IN3312DEN2012A IN2012DN03312A IN 2012DN03312 A IN2012DN03312 A IN 2012DN03312A IN 3312DEN2012 A IN3312DEN2012 A IN 3312DEN2012A IN 2012DN03312 A IN2012DN03312 A IN 2012DN03312A
- Authority
- IN
- India
- Prior art keywords
- compounds
- relates
- present
- heteroarylcarbonyl
- arylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25388909P | 2009-10-22 | 2009-10-22 | |
PCT/AU2010/001398 WO2011047432A1 (en) | 2009-10-22 | 2010-10-21 | Fused ring analogues of anti-fibrotic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03312A true IN2012DN03312A (en) | 2015-10-23 |
Family
ID=43899730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3312DEN2012 IN2012DN03312A (en) | 2009-10-22 | 2010-10-21 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9062076B2 (en) |
EP (2) | EP2491030B1 (en) |
JP (3) | JP5904944B2 (en) |
CN (2) | CN102574843B (en) |
HK (2) | HK1217480A1 (en) |
IN (1) | IN2012DN03312A (en) |
SG (1) | SG10201501272SA (en) |
WO (1) | WO2011047432A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (en) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-heteroaryl carboxamides |
EP2799427B1 (en) | 2006-07-05 | 2018-07-04 | Fibrotech Therapeutics PTY LTD | Therapeutic compounds |
ES2740424T3 (en) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Methods and compositions for disorders related to cell proliferation |
CA2758071C (en) | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
AU2010266386C1 (en) | 2009-06-29 | 2017-03-09 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
ES2594402T3 (en) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for disorders related to cell proliferation |
EP2491030B1 (en) | 2009-10-22 | 2015-07-15 | Fibrotech Therapeutics PTY LTD | Fused ring analogues of anti-fibrotic agents |
CA2989633A1 (en) | 2010-05-17 | 2011-11-24 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
HUE042676T2 (en) | 2010-11-24 | 2019-07-29 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
ES2569712T3 (en) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | PKM2 bicyclic activators |
TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
WO2012151452A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
CA2834602C (en) | 2011-05-03 | 2020-10-06 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR102089239B1 (en) | 2012-04-24 | 2020-03-16 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk inhibitors |
CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
MX350418B (en) * | 2012-06-27 | 2017-09-06 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders. |
FR2994184B1 (en) * | 2012-08-02 | 2017-12-08 | Biomerieux Sa | METHODS OF FUNCTIONALIZATION AND REAGENTS USED IN SUCH METHODS USING AN AZA-ISATOIC ANHYDRIDE OR ONE OF ITS DERIVATIVES, BIOLOGIC MOLECULES SO TREATED AND KITS |
EP3527563B1 (en) | 2013-03-12 | 2021-09-01 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015006591A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
AR097279A1 (en) * | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS |
US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
SG11201602445SA (en) | 2013-10-04 | 2016-04-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
ES2705342T3 (en) | 2013-10-17 | 2019-03-22 | Vertex Pharma | Co-crystals of (S) -N-methyl-8- (1 - ((2'-methyl- [4,5'-bipirimidin] -6-yl) amino) propan-2-yl) quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors |
CN112159391A (en) | 2014-03-14 | 2021-01-01 | 阿吉奥斯制药公司 | Pharmaceutical compositions of therapeutically active compounds |
WO2015143012A1 (en) | 2014-03-19 | 2015-09-24 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015171610A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
CN104761506B (en) * | 2015-04-10 | 2017-05-03 | 温州大学 | 2-(1-styryl)quinazolone compounds and synthesis method thereof |
SI3307271T1 (en) | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
CN108349985A (en) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | Solid form, preparation method, the composition and its application method comprising it of isoquinolines |
MX2018004586A (en) | 2015-10-15 | 2018-08-16 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies. |
IL258684B2 (en) | 2015-10-15 | 2023-04-01 | Agios Pharmaceuticals Inc | Combination therapy comprising isocitrate dehydrogenase 1 (idh1) inhibitor for use in treating acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 |
CN105175416B (en) * | 2015-10-20 | 2017-12-22 | 中国药科大学 | A kind of new histon deacetylase (HDAC) inhibitor |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
WO2018144620A1 (en) * | 2017-02-03 | 2018-08-09 | Shire Human Genetic Therapies, Inc. | Anti-fibrotic compounds |
GB201721961D0 (en) * | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
EP3746437B1 (en) | 2018-01-31 | 2024-08-21 | HepaRegeniX GmbH | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN110483432A (en) * | 2018-05-14 | 2019-11-22 | 中国科学院上海药物研究所 | A kind of acrylic compounds and preparation method thereof, pharmaceutical composition and purposes |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11912701B2 (en) | 2018-07-16 | 2024-02-27 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN113874015B (en) | 2018-12-21 | 2024-05-24 | 细胞基因公司 | Thienopyridine inhibitors of RIPK2 |
CN109705140A (en) * | 2019-01-08 | 2019-05-03 | 荆楚理工学院 | A kind of synthetic method of pyrido [2,3-d] [1,3] oxazines derivative |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
CR20230057A (en) | 2020-07-02 | 2023-08-15 | Incyte Corp | Tricyclic urea compounds as jak2 v617f inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
CN114831977B (en) * | 2021-02-02 | 2023-12-19 | 北京大学 | Application of benzoic acid derivative as TRPM2 protein inhibitor |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
WO2024131942A1 (en) * | 2022-12-23 | 2024-06-27 | 上海深势唯思科技有限责任公司 | Cyclopropane tlr7 and tlr8 inhibitor, preparation method therefor, and use thereof |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5640710B2 (en) | 1973-01-18 | 1981-09-22 | ||
JPS5830302B2 (en) | 1974-04-16 | 1983-06-28 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | Shinki Hōkōzoku Carbon Sanamide Yudōtai no Seizō Hōhō |
JPS5848545B2 (en) | 1974-04-18 | 1983-10-28 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | Shinki Hōkōzoku Carbon Sanamide Yudōtai no Seizō Hōhō |
JPS511440A (en) | 1974-04-18 | 1976-01-08 | Kissei Pharmaceutical | SHINKIHOKOZOKUKARUBONSANJUDOTAI NO SEIZOHOHO |
GB1484413A (en) | 1974-04-18 | 1977-09-01 | Kissei Pharmaceutical | Aromatic amidocarboxylic acid derivatives |
JPS5855138B2 (en) | 1975-12-31 | 1983-12-08 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | Houkozoku carbon sanamide |
JPS6019738B2 (en) | 1978-03-20 | 1985-05-17 | 久光製薬株式会社 | Novel anthranilic acid derivative |
JPS5576852A (en) | 1978-12-01 | 1980-06-10 | Hisamitsu Pharmaceut Co Inc | Novel derivative of anthranilic acid |
JPS5817186B2 (en) | 1981-01-23 | 1983-04-05 | キツセイ薬品工業株式会社 | Method for producing novel aromatic carboxylic acid derivatives |
US4587356A (en) | 1981-09-01 | 1986-05-06 | Kissei Pharmaceutical Co., Ltd. | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives |
JPS6019754A (en) | 1983-07-14 | 1985-01-31 | Kissei Pharmaceut Co Ltd | Production of aromatic carboxylic acid amide derivative |
JPS60152454A (en) | 1984-01-18 | 1985-08-10 | Terumo Corp | Amide derivative and 5-lipoxigenase inhibitor containing said derivative as active component |
JPS6191163A (en) * | 1984-10-08 | 1986-05-09 | Fujimoto Seiyaku Kk | Preparation of anthranylic acid derivative |
DE3505609A1 (en) | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | BENZIMIDAZOLYL PYRIDAZINONE |
JPS625966A (en) * | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | Benzimidazole derivative |
JPH0692353B2 (en) | 1987-05-26 | 1994-11-16 | マルコ製薬株式会社 | Novel aminobenzoic acid amide derivative and method for producing the same |
JPS6416755A (en) | 1987-06-23 | 1989-01-20 | Biogal Gyogyszergyar | Manufacture of n-(3',4'-dimethoxycinnamoyl)-aniline derivative |
JPH01287066A (en) | 1988-05-13 | 1989-11-17 | Fujimoto Seiyaku Kk | Novel anthranilic acid derivative |
JPH07116029B2 (en) | 1989-04-04 | 1995-12-13 | キッセイ薬品工業株式会社 | Tranilast aqueous solution formulation |
WO1991012237A1 (en) | 1990-02-08 | 1991-08-22 | Eisai Co., Ltd. | Benzenesulfonamide derivative |
US5248825A (en) | 1990-09-20 | 1993-09-28 | Merrell Dow Pharmaceuticals Inc. | Calcium uptake inhibitors |
DE4115184A1 (en) | 1991-05-09 | 1992-11-12 | Bayer Ag | BENZOTHIOPHEN-2-CARBOXAMID-S, S-DIOXIDE |
US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
EP0657422B1 (en) | 1993-12-09 | 1998-06-10 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives as PGE2 agonists and antagonists |
EP0785927B1 (en) | 1994-10-12 | 2003-08-27 | Euroceltique S.A. | Novel benzoxazoles |
US5665737B1 (en) * | 1994-10-12 | 1999-02-16 | Euro Celtique Sa | Substituted benzoxazoles |
JPH08113567A (en) | 1994-10-17 | 1996-05-07 | Sando Yakuhin Kk | Phenylethenyl derivative and 5-lipoxygenase inhibitor containing the same |
US6444694B1 (en) * | 1995-06-06 | 2002-09-03 | Wyeth | Styryl benzimidazole derivatives |
JPH08337523A (en) | 1995-06-14 | 1996-12-24 | Taiho Yakuhin Kogyo Kk | Vascularization inhibitor |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
ES2151464T3 (en) | 1996-02-07 | 2002-12-16 | Lead Chem Co Ltd | PREPARATION FOR EXTERNAL APPLICATION THAT INCLUDES TRANILAST AND PROCEDURE TO PRODUCE IT. |
EP0894496A4 (en) | 1996-02-15 | 2001-01-03 | Kissei Pharmaceutical | Neovascularization inhibitor |
JPH09278653A (en) | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | Retinal disease-treating preparation |
DE19624155A1 (en) | 1996-06-18 | 1998-01-08 | Hoechst Ag | Substituted benzoic acid derivatives, process for their preparation and the use of the compounds for the treatment of diseases |
GB9625913D0 (en) * | 1996-12-13 | 1997-01-29 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their seco precursors,and their use as prodrugs |
JPH10259129A (en) | 1997-01-16 | 1998-09-29 | Kissei Pharmaceut Co Ltd | Arterialization inhibitor |
FR2759368B1 (en) | 1997-02-10 | 2001-06-01 | Galderma Rech Dermatologique | BIAROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM, AND USES |
JPH10306024A (en) | 1997-03-07 | 1998-11-17 | Kissei Pharmaceut Co Ltd | Preventive and therapeutic agent against glomerular disease |
TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
JPH10330254A (en) | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | Suppressant for progress of pterygium and postoperative relapse |
US6127392A (en) | 1997-08-05 | 2000-10-03 | American Home Products Corporation | Anthranilic acid analogs |
JPH11180952A (en) * | 1997-12-19 | 1999-07-06 | Maruho Co Ltd | 2-oxindole derivative |
JP3256513B2 (en) | 1998-02-11 | 2002-02-12 | ファイザー製薬株式会社 | Benzimidazole cyclooxygenase-2 inhibitor |
BR9912571A (en) * | 1998-07-28 | 2001-11-20 | Nihon Nohyaku Co Ltd | Derived from fused dicarboxylic heterocyclic acid diamide, herbicide, and process for using a herbicide |
EP1140896A1 (en) | 1998-12-21 | 2001-10-10 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
CN1789246A (en) * | 1999-06-02 | 2006-06-21 | Nps药物有限公司 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
DE19935219A1 (en) | 1999-07-27 | 2001-02-01 | Boehringer Ingelheim Pharma | Carboxamides, medicines containing these compounds, their use and manufacture |
PL353455A1 (en) | 1999-08-12 | 2003-11-17 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
AU2001251083A1 (en) * | 2000-03-31 | 2001-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists |
GB0019950D0 (en) * | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
CN1315805C (en) * | 2000-09-19 | 2007-05-16 | 斯皮罗根公司 | Compositions and methods of use thereof achiral analogues of CC-1065 and duocarmycins |
AU2002234236A1 (en) | 2001-01-10 | 2002-07-24 | Smithkline Beecham Corporation | Process and product |
GB2372986A (en) * | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
DE60205465T2 (en) | 2001-01-23 | 2006-04-20 | Eli Lilly And Co., Indianapolis | PIPERAZINE DERIVATIVES AS AGONISTS OF THE MELANOCORTIN RECEPTOR |
WO2002066454A1 (en) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Chromene derivatives |
JP4171656B2 (en) | 2001-02-28 | 2008-10-22 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | N- (aryl) -2-arylethenesulfonamide and its pharmaceutical use |
AR034897A1 (en) * | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | N-MONOACILATED DERIVATIVES OF O-PHENYLENDIAMINS, THEIR HETEROCICLICAL ANALOGS OF SIX MEMBERS AND THEIR USE AS PHARMACEUTICAL AGENTS |
US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
JP4851671B2 (en) | 2001-10-11 | 2012-01-11 | ニチバン株式会社 | Tranilast transdermal patch and method for producing the same |
TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
US7622479B2 (en) | 2001-11-26 | 2009-11-24 | Takeda Pharmaceutical Company Limited | Bicyclic derivative, its production and use |
US6759428B2 (en) * | 2001-12-04 | 2004-07-06 | Roche Palo Alto Llc | Indole nitriles |
EP1463714A4 (en) | 2001-12-10 | 2005-10-19 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
US7408063B2 (en) * | 2001-12-19 | 2008-08-05 | Janssen Pharmaceutica, N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
TW200303302A (en) | 2001-12-19 | 2003-09-01 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
MXPA04006386A (en) | 2001-12-27 | 2005-03-31 | Taisho Pharma Co Ltd | Carboxylic acid derivative. |
DE60320933D1 (en) | 2002-01-10 | 2008-06-26 | Bayer Healthcare Ag | RHO-KINASE INHIBITORS |
JP2004143134A (en) | 2002-02-13 | 2004-05-20 | Takeda Chem Ind Ltd | Jnk inhibitor |
JP2004075614A (en) * | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | Pharmaceutical containing chromene derivative |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
WO2004022525A1 (en) | 2002-09-05 | 2004-03-18 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
DE10254872A1 (en) | 2002-11-25 | 2004-06-03 | Symrise Gmbh & Co. Kg | Anthranilic acid amides and their derivatives as cosmetic and pharmaceutical active ingredients |
CN1506359A (en) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | Coumarin amide derivative and its prepn, medicinal composition and use |
WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
JP4638410B2 (en) * | 2003-04-30 | 2011-02-23 | ノバルティス アーゲー | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
US7691870B2 (en) | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole carboxamides as raf kinase inhibitors |
US20050026944A1 (en) | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
US7250444B2 (en) | 2003-08-11 | 2007-07-31 | Pfizer Inc. | Pyrrole-based HMG-CoA reductase inhibitors |
GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
KR101153335B1 (en) | 2003-09-24 | 2012-07-05 | 메틸진 인코포레이티드 | Inhibitors of histone deacetylase |
CN1882529A (en) * | 2003-09-24 | 2006-12-20 | 梅特希尔基因公司 | Inhibitors of histone deacetylase |
DE10346913A1 (en) | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | acylhydrazone |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
AU2005253966B2 (en) | 2004-06-08 | 2012-01-19 | Temple University Of The Commonwealth System Of Higher Education | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof |
WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
BRPI0512623A (en) | 2004-06-25 | 2008-03-25 | Janssen Phamaceutica N V | ccr2 antagonist quaternary salt |
DE102004030987A1 (en) | 2004-06-26 | 2006-01-12 | Merck Patent Gmbh | Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides |
US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
AU2005268030B2 (en) | 2004-08-06 | 2009-02-19 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds |
JP2008518957A (en) | 2004-11-04 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
EP1824469A4 (en) | 2004-11-17 | 2008-07-30 | Nuon Therapeutics Pty Ltd | A method of modulating b cell functioning |
CA2587207A1 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
ITMI20050261A1 (en) | 2005-02-21 | 2006-08-22 | Carlo Ghisalberti | STRUCTURAL ANALOGS OF AVENATRAMIDS THEIR USE IN USEFUL COMPOSITIONS IN THE TREATMENT OF DERMATOLOGICAL DISORDERS |
AU2006218403A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
CA2602583A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
ZA200708786B (en) | 2005-03-30 | 2009-01-28 | Yakult Honsha Kk | BCRP/ABCG2 inhibitor |
ITMI20050674A1 (en) | 2005-04-15 | 2006-10-16 | Univ Degli Studi Milano | USE OF AMIDID DERIVATIVES AS A TASTING AGENT OF TASTE FLAVORED COMPOSITIONS AND PRODUCTS THAT CONTAIN THEM |
US7786137B2 (en) * | 2005-05-10 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
KR20080016859A (en) | 2005-05-16 | 2008-02-22 | 앤지오젠 파마슈티칼스 피티와이. 리미티드 | Methods and compositions for the treatment of pain |
WO2006134013A1 (en) | 2005-06-14 | 2006-12-21 | Symrise Gmbh & Co. Kg | Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching |
WO2007015744A1 (en) | 2005-07-21 | 2007-02-08 | Incyte Corporation | Disubstituted thienyl compounds and their use as pharmaceuticals |
US8911795B2 (en) | 2005-11-30 | 2014-12-16 | Symrise Ag | Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
AU2007234843B2 (en) * | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US20070286892A1 (en) | 2006-06-13 | 2007-12-13 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
ES2462925T3 (en) | 2006-06-14 | 2014-05-26 | Symrise Ag | Compounds with antimicrobial effect for the treatment of oral fetidity |
US20090286863A1 (en) | 2006-07-05 | 2009-11-19 | David Bruge | Sulfamatobenzothiophene derivatives |
EP2799427B1 (en) | 2006-07-05 | 2018-07-04 | Fibrotech Therapeutics PTY LTD | Therapeutic compounds |
KR100832747B1 (en) | 2006-10-27 | 2008-05-27 | 한국화학연구원 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating an ischemic disease containing the same |
US7968577B2 (en) | 2006-11-01 | 2011-06-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
AU2007317349B2 (en) * | 2006-11-03 | 2011-10-20 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2008073461A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
PE20121126A1 (en) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
WO2008109238A1 (en) | 2007-03-02 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted cyclopentyl piperidine ccr2 antagonists |
EP1972624A1 (en) | 2007-03-23 | 2008-09-24 | Clariant International Ltd. | Benzoxazinones and their use as ultraviolet light absorbers |
US20090239982A1 (en) | 2007-03-30 | 2009-09-24 | Fujifilm Corporation | Ultraviolet Absorbent and Heterocyclic Compound |
MX2009010523A (en) | 2007-04-10 | 2009-12-15 | Lundbeck & Co As H | Heteroaryl amide analogues as p2x7 antagonists. |
AU2008267081B2 (en) * | 2007-06-12 | 2013-05-09 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
EP2030617A1 (en) | 2007-08-17 | 2009-03-04 | Sygnis Bioscience GmbH & Co. KG | Use of tranilast and derivatives thereof for the therapy of neurological conditions |
KR101257550B1 (en) | 2007-09-10 | 2013-04-24 | 칼시메디카, 인크 | Compounds that modulate intracellular calcium |
TWI440638B (en) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | Heterocyclic compound and pharmaceutical composition thereof |
US20090170842A1 (en) * | 2007-11-14 | 2009-07-02 | University Of Kansas | Brca1-based breast or ovarian cancer prevention agents and methods of use |
WO2009068557A1 (en) | 2007-11-28 | 2009-06-04 | Neurosearch A/S | Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators |
US20110052562A1 (en) * | 2007-12-19 | 2011-03-03 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
US20090163586A1 (en) | 2007-12-20 | 2009-06-25 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 205 |
WO2009079692A1 (en) | 2007-12-21 | 2009-07-02 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
CN101481323B (en) | 2008-01-11 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Benzo cyclohepten derivate, and preparation and medical use thereof |
EP2321303B1 (en) * | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
CN101423503A (en) | 2008-12-04 | 2009-05-06 | 上海大学 | 2-(trans-2,3-dihydro-2-aryl-1-cyano-3-carbomethoxyl cyclopropane)-1,3-benzopyrene and synthetic method thereof |
WO2010103130A2 (en) * | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
EP2491030B1 (en) | 2009-10-22 | 2015-07-15 | Fibrotech Therapeutics PTY LTD | Fused ring analogues of anti-fibrotic agents |
-
2010
- 2010-10-21 EP EP10824314.8A patent/EP2491030B1/en not_active Not-in-force
- 2010-10-21 EP EP15169791.9A patent/EP2947073B1/en not_active Not-in-force
- 2010-10-21 IN IN3312DEN2012 patent/IN2012DN03312A/en unknown
- 2010-10-21 US US13/503,160 patent/US9062076B2/en not_active Expired - Fee Related
- 2010-10-21 SG SG10201501272SA patent/SG10201501272SA/en unknown
- 2010-10-21 CN CN201080047294.3A patent/CN102574843B/en not_active Expired - Fee Related
- 2010-10-21 CN CN201510259423.XA patent/CN105153188B/en not_active Expired - Fee Related
- 2010-10-21 JP JP2012534495A patent/JP5904944B2/en not_active Expired - Fee Related
- 2010-10-21 WO PCT/AU2010/001398 patent/WO2011047432A1/en active Application Filing
-
2015
- 2015-06-04 US US14/730,753 patent/US9951087B2/en active Active
- 2015-10-15 JP JP2015203785A patent/JP6215890B2/en not_active Expired - Fee Related
-
2016
- 2016-05-10 HK HK16105337.3A patent/HK1217480A1/en not_active IP Right Cessation
- 2016-05-26 HK HK16106007.0A patent/HK1217951A1/en not_active IP Right Cessation
-
2017
- 2017-07-28 JP JP2017146253A patent/JP6437060B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN105153188A (en) | 2015-12-16 |
CN102574843B (en) | 2015-06-17 |
WO2011047432A1 (en) | 2011-04-28 |
JP5904944B2 (en) | 2016-04-20 |
EP2947073A2 (en) | 2015-11-25 |
US20120270863A1 (en) | 2012-10-25 |
CN102574843A (en) | 2012-07-11 |
SG10201501272SA (en) | 2015-04-29 |
EP2947073A3 (en) | 2016-02-17 |
JP6215890B2 (en) | 2017-10-18 |
JP2016128401A (en) | 2016-07-14 |
JP2018012700A (en) | 2018-01-25 |
US9951087B2 (en) | 2018-04-24 |
EP2491030A4 (en) | 2013-04-17 |
EP2491030B1 (en) | 2015-07-15 |
EP2947073B1 (en) | 2019-04-03 |
US9062076B2 (en) | 2015-06-23 |
HK1217480A1 (en) | 2017-01-13 |
JP2013508306A (en) | 2013-03-07 |
US20130338151A9 (en) | 2013-12-19 |
JP6437060B2 (en) | 2018-12-12 |
HK1217951A1 (en) | 2017-01-27 |
CN105153188B (en) | 2018-06-01 |
US20150266893A1 (en) | 2015-09-24 |
EP2491030A1 (en) | 2012-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03312A (en) | ||
IN2014DN10386A (en) | ||
GB201118656D0 (en) | New compounds | |
WO2012174487A8 (en) | Bromodomain inhibitors and uses thereof | |
WO2012151512A3 (en) | Bromodomain inhibitors and uses thereof | |
PH12015500724A1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
MX345535B (en) | Partially saturated tricyclic compounds and methods of making and using same. | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
MY165826A (en) | Pharmaceutical composition | |
MX348823B (en) | Stable formulations of linaclotide. | |
MX2019012939A (en) | Linaclotide-containing formulations for oral administration. | |
MX2011013032A (en) | Inhibitors of phosphatidylinositol 3-kinase. | |
MX342947B (en) | Treatment of type 2 diabetes. | |
MX2013013649A (en) | Quinone compounds for treating ape1 mediated diseases. | |
MX2013002118A (en) | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators. | |
IN2012DN00239A (en) | ||
MX2015000179A (en) | Itraconazole compositions and dosage forms, and methods of using the same. | |
WO2013038200A3 (en) | Neurodevelopmental disorders | |
IN2013MU01241A (en) | ||
IN2013MU01242A (en) | ||
IN2013MU01240A (en) | ||
IN2013MU02059A (en) | ||
IN2013MU01250A (en) | ||
IN2013MU01249A (en) | ||
IN2013MU01248A (en) |